Malaria is a lethal disease causing devastating global impact by killing more than 8,00,000
individuals yearly. A noticeable decline in malaria related deaths can be attributed to the most reliable
treatment, ACTs against P. falciparum. However, the cumulative resistance of the malaria parasite
against ACTs is a global threat to control the disease and, therefore the new effective therapeutics are
urgently needed, including new treatment approaches. Majority of the antimalarial drugs target BS malarial
infection. Currently, scientists are eager to explore the drugs with potency against not only BS but
other life stages such as sexual and asexual stages of the malaria parasite. Liver Stage is considered as
one of the important drug targets as it always leads to BS and the infection can be cured at this stage before
it enters into the Blood Stage. However, a limited number of compounds are reported effective
against LS malaria infection probably due to scarcity of in vitro LS culture methods and clinical possibilities.
This mini review covers a range of chemical compounds showing efficacy against BS and LS of
the malaria parasite’s life cycle collectively (i.e. dual stage activity). These scaffolds targeting dual
stages are essential for the eradication of malaria and to evade resistance.
Keywords: Antimalarials, Chloroquine (CQ) resistance, Plasmodium falciparum (Pf), Artemisinin-based combination therapy
(ACT), Hybrid molecules, Malaria.
Rights & PermissionsPrintExport